| pubmed-article:17959343 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17959343 | lifeskim:mentions | umls-concept:C0030193 | lld:lifeskim |
| pubmed-article:17959343 | lifeskim:mentions | umls-concept:C0006931 | lld:lifeskim |
| pubmed-article:17959343 | lifeskim:mentions | umls-concept:C0343757 | lld:lifeskim |
| pubmed-article:17959343 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:17959343 | lifeskim:mentions | umls-concept:C0994894 | lld:lifeskim |
| pubmed-article:17959343 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17959343 | pubmed:dateCreated | 2008-2-25 | lld:pubmed |
| pubmed-article:17959343 | pubmed:abstractText | Peripheral neuropathy is the most frequent neurological complication of human immunodeficiency virus (HIV)-1 infection and is commonly associated with the development of chronic pain. This open-label, 12-week pilot study assessed the efficacy, tolerability, and safety of a high-concentration capsaicin dermal patch (NGX-4010; capsaicin, 640microg/cm2, 8% w/w) to treat painful HIV-associated distal sensory polyneuropathy (DSP). Eligible patients had moderate-to-severe pain in both feet due to HIV-associated DSP or antiretroviral toxic neuropathy. Patients received a single 60-minute application of the investigational high-concentration capsaicin patch to the affected areas. The primary outcome measure was the mean percent change in numeric pain rating scale (NPRS) during weeks two to 12 postadministration. After a single 60-minute NGX-4010 application, the mean percent change from baseline in "average pain for past 24 hours" NPRS scores during weeks two to 12 was -40% (95% CI: -61%, -19%; P=0.0020). Similar results were observed for "worst pain for past 24 hours" and "pain now" scores. Eight of 12 patients (67%) were treatment responders (> or =30% pain decrease). Four of 12 patients (33%) experienced a > or =50% reduction in pain. Treatment was generally well tolerated. Treatment-associated pain was self-limited and could be managed with short-acting opioids. This study demonstrates that treatment of painful HIV-associated neuropathy with a single application of NGX-4010, a high-concentration capsaicin patch, was feasible, well tolerated, and associated with significant reduction in pain over the 12 weeks studied. No safety concerns were identified. Controlled studies of NGX-4010 for the treatment of painful HIV-associated neuropathy are warranted. | lld:pubmed |
| pubmed-article:17959343 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17959343 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17959343 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17959343 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17959343 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17959343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17959343 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17959343 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17959343 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17959343 | pubmed:issn | 0885-3924 | lld:pubmed |
| pubmed-article:17959343 | pubmed:author | pubmed-author:SimpsonDavid... | lld:pubmed |
| pubmed-article:17959343 | pubmed:author | pubmed-author:SampsonJamesJ | lld:pubmed |
| pubmed-article:17959343 | pubmed:author | pubmed-author:BrownStephen... | lld:pubmed |
| pubmed-article:17959343 | pubmed:author | pubmed-author:EstanislaoLyd... | lld:pubmed |
| pubmed-article:17959343 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17959343 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:17959343 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17959343 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17959343 | pubmed:pagination | 299-306 | lld:pubmed |
| pubmed-article:17959343 | pubmed:dateRevised | 2008-7-1 | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:meshHeading | pubmed-meshheading:17959343... | lld:pubmed |
| pubmed-article:17959343 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17959343 | pubmed:articleTitle | An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. | lld:pubmed |
| pubmed-article:17959343 | pubmed:affiliation | Mount Sinai School of Medicine, New York, NY 10029, USA. david.simpson@mssm.edu | lld:pubmed |
| pubmed-article:17959343 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17959343 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17959343 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17959343 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17959343 | lld:pubmed |
